CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,196)	$ (2,417)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	6	0
Depreciation	10	9
Amortization of debt issuance costs and discounts	244	110
Stock-based compensation	377	120
Change in fair value of derivative liability	(65)	18
Amortization of lease right-of-use-asset	97	86
Loss on extinguishment of debt	533	0
Gain from forgiveness of debt	(96)	(69)
Other non-cash expenses	33	21
Change in operating assets and liabilities:
Accounts receivable	(7)	6
Inventory	185	(1)
Other current assets	208	120
Accounts payable and accrued liabilities	1,363	545
Lease liabilities	(100)	(92)
Deferred revenue	(660)	425
NET CASH USED IN OPERATING ACTIVITIES	(1,068)	(1,119)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(2)	0
NET CASH USED FOR INVESTING ACTIVITIES	(2)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of notes payable	588	512
Proceeds from the issuance of notes payable issued to related parties	160	75
Payments made on notes payable	(499)	(438)
Payments made on notes payable issued to related parties	(41)	(39)
Payments of debt issuance costs	(30)	(29)
Proceeds from issuance of common stock and warrants in private placement offerings	567	835
NET CASH PROVIDED BY FINANCING ACTIVITIES	745	916
NET CHANGE IN CASH	(325)	(203)
Cash at beginning of period	388	591
CASH AT END OF PERIOD	63	388
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	61	51
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	150	174
Common stock issued for payment of interest	186	126
Common stock issued for payment of accrued dividends	183	177
Conversion of Preferred Stock Series C to common stock	105	0
Conversion of Preferred Stock Series C1 to common stock	109	0
Conversion of Preferred Stock Series C2 to common stock	439	0
Conversion of Preferred Stock Series D to common stock	140	0
Conversion of Preferred Stock Series E to common stock	550	0
Conversion of Preferred Stock Series F to common stock	0	21
Conversion of Preferred Stock Series F-2 to common stock	37	0
Conversion of debt and accrued interest into common stock	102	0
Directors and Officers Insurance obtained with Financing	125	130
Non-cash lease liability remeasurement	642
Warrants issued with debt	17	136
Inception of derivative liability	50	100
Accrued payroll liability exchanged for promissory note	0	87
Settlement of previously accrued professional fees through common stock issuance	$ 0	$ 114

GUIDED THERAPEUTICS INC 10-K